Ampicillin Trihydrate

Urinary Tract Infections, Endocarditis, Whooping Cough + 17 more

Treatment

19 FDA approvals

20 Active Studies for Ampicillin Trihydrate

Treatment for

Urinary Tract Infections

What is Ampicillin Trihydrate

Ampicillin

The Generic name of this drug

Treatment Summary

Ampicillin is a type of oral antibiotic derived from penicillin. It works against a wide range of bacterial infections.

Ampicillin

is the brand name

Ampicillin Trihydrate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ampicillin

1971

270

Approved as Treatment by the FDA

Ampicillin, also called Ampicillin, is approved by the FDA for 19 uses such as Recurrent Upper and Lower Respiratory Tract Infections (RTIs) and Infection caused by eikenella corrodens .

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Infection caused by eikenella corrodens

disease caused by Salmonella typhi

bacterial skin infections

Urinary Tract Infection (UTI)

Used to treat Bacterial Infections in combination with Sulbactam

Pertussis

Gastrointestinal Tract Infections

Bacterial Infections

Used to treat Bacterial Infections in combination with Sulbactam

perinatal group B streptococcus

Salmonella

Shigella

Listeria infection

Disease

Bacterial Infections

Urinary Tract Infections

Respiratory Tract Infections

Communicable Diseases

Listeriosis

Whooping Cough

Effectiveness

How Ampicillin Trihydrate Affects Patients

Ampicillin is an antibiotic used to treat bacterial infections that are usually caused by certain types of bacteria. It is part of the group of antibiotics called penicillin, which can fight both gram-positive and gram-negative bacteria. Ampicillin works by preventing bacteria from building cell walls, which is done by binding to special proteins in the bacteria. It is also resistant to many beta-lactamases, which are enzymes that can destroy certain types of antibiotics.

How Ampicillin Trihydrate works in the body

Ampicillin works by attaching to certain proteins found in bacterial cell walls. This prevents the bacteria from finishing the process of building its cell wall, which ultimately causes the bacteria to break apart and die. It is also believed that Ampicillin may interfere with a compound that stops certain enzymes from breaking down the cell wall.

When to interrupt dosage

The measure of Ampicillin Trihydrate relies upon the determined sickness, including Salmonella, Urinary Tract Infection and perinatal group B streptococcus. The dosage varies as per the mode of delivery (e.g. Injection, powder, for solution - Intramuscular; Intravenous or Injection, powder, for solution) noted in the following table.

Condition

Dosage

Administration

Disease

, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg

, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Capsule, Capsule - Oral, Oral, Liquid - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid, Liquid - Intramuscular; Intravenous, Tablet, Tablet - Oral, Suspension - Oral, Capsule; Tablet - Oral

Urinary Tract Infections

Endocarditis

Shigella

Respiratory Tract Infections

Gastrointestinal Tract Infections

Bacterial Infections

Urinary Tract Infections

Whooping Cough

Communicable Diseases

perinatal group B streptococcus

Salmonella

Meningitis, Bacterial

Septicemia

Listeriosis

Urinary Tract Infection (UTI)

Cesarean Section

Hysterectomy, Vaginal

Infection

Warnings

Ampicillin Trihydrate has one contraindication, so it should not be ingested for the conditions presented in the following table.

Ampicillin Trihydrate Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Ampicillin may interact with Pulse Frequency

There are 20 known major drug interactions with Ampicillin Trihydrate.

Common Ampicillin Trihydrate Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ampicillin.

Abacavir

Minor

Ampicillin may decrease the excretion rate of Abacavir which could result in a higher serum level.

Aclidinium

Minor

Ampicillin may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Ampicillin may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Albutrepenonacog alfa

Minor

Ampicillin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Ampicillin Trihydrate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ampicillin Trihydrate?

67 active studies are currently being conducted to investigate the potential of Ampicillin Trihydrate in combating Urinary Tract Infection, Communicable Diseases, and Endocarditis.

Condition

Clinical Trials

Trial Phases

Infection

6 Actively Recruiting

Not Applicable, Phase 1

Meningitis, Bacterial

0 Actively Recruiting

Endocarditis

1 Actively Recruiting

Not Applicable

Shigella

2 Actively Recruiting

Phase 2, Phase 1

Bacterial Infections

0 Actively Recruiting

Cesarean Section

1 Actively Recruiting

Phase 4

Septicemia

1 Actively Recruiting

Not Applicable

Urinary Tract Infections

0 Actively Recruiting

Whooping Cough

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Communicable Diseases

0 Actively Recruiting

Listeriosis

0 Actively Recruiting

Urinary Tract Infections

9 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1

Disease

0 Actively Recruiting

Gastrointestinal Tract Infections

0 Actively Recruiting

Hysterectomy, Vaginal

1 Actively Recruiting

Phase 4

Respiratory Tract Infections

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

Salmonella

0 Actively Recruiting

perinatal group B streptococcus

0 Actively Recruiting

Patient Q&A Section about ampicillin trihydrate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is amoxicillin trihydrate used to treat?

"It is used to treat bacterial infections, such as chest infections (including pneumonia) and dental abscesses. It can also be used together with other antibiotics and medicines to treat stomach ulcers. It's often prescribed for children, to treat ear infections and chest infections. Eradacil can also be used to treat other conditions as determined by your doctor."

Answered by AI

What is the meaning of ampicillin trihydrate?

"Ampicillin Trihydrate prevents bacteria from making new cell walls, which eventually leads to the death of the bacteria. This is achieved by binding to proteins that are essential for cell wall synthesis."

Answered by AI

What is ampicillin trihydrate used for?

"It will not work for viral infections (such as common cold, flu).

Ampicillin is used to treat a wide variety of bacterial infections. It is a penicillin-type antibiotic that works by stopping the growth of bacteria. This antibiotic only treats bacterial infections and will not work for viral infections such as the common cold or flu."

Answered by AI

Is ampicillin a strong antibiotic?

"Ampicillin can be an effective antibiotic against a variety of bacteria but is not as commonly prescribed as it used to be because resistance can occur when it is used alone."

Answered by AI

Clinical Trials for Ampicillin Trihydrate

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17

All Sexes

Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4

Waitlist Available

New This Month

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+

All Sexes

Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available

Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD